Literature DB >> 21180609

Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats.

Ilan Aroch1, Sarah Kraus, Inna Naumov, Ehud Ron, Shiran Shapira, Dina Kazanov, Nis Giladi, Alex Litvak, Shahar Lev-Ari, Aharon Hallak, Iris Dotan, Baruch Shpitz, Nadir Arber.   

Abstract

OBJECTIVES: Coltect is a novel dietary supplement containing curcumin, green tea and selenomethionine. Previous reports have suggested that these agents can prevent colorectal cancer (CRC). The present study examined the chemopreventive effect of Coltect alone or combined with 5-aminosalicylic acid (5-ASA) using the 1,2-dimethylhydrazine (DMH) model in rats.
METHODS: The effect of Coltect was examined on HT-29 CRC cells by growth inhibition assay. Apoptosis was determined by annexin V-FITC/PI staining. Male rats were injected with DMH in vivo and treated with Coltect 150 mg/kg, 5-ASA 50 mg/kg or their combination, by oral gavage. Aberrant crypt foci (ACF) were identified by methylene blue staining.
RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in cancer cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of ACF was divided into small (1-3 crypts) or large (≥4 crypts). The Coltect compound reduced the number of small and large ACF similarly to 5-ASA (40% reduction). This reduction was amplified by combining the two agents (70% reduction).
CONCLUSION: Coltect inhibits the growth of colon cancer cells, induces apoptosis and inhibits ACF development. Furthermore, it augments the growth inhibitory effect of 5-ASA in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of CRC.

Entities:  

Keywords:  5-aminosalicylic acid; Coltect; aberrant crypt foci; chemoprevention; colorectal cancer

Year:  2010        PMID: 21180609      PMCID: PMC3002588          DOI: 10.1177/1756283X10379258

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  36 in total

1.  Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.

Authors:  Baruch Shpitz; Nis Giladi; Eyal Sagiv; Shahar Lev-Ari; Eliezer Liberman; Diana Kazanov; Nadir Arber
Journal:  Digestion       Date:  2007-01-15       Impact factor: 3.216

2.  Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.

Authors:  B Agarwal; C V Rao; S Bhendwal; W R Ramey; H Shirin; B S Reddy; P R Holt
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

Review 3.  Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat.

Authors:  R H Dashwood; M Xu; J F Hernaez; N Hasaniya; K Youn; A Razzuk
Journal:  Proc Soc Exp Biol Med       Date:  1999-04

4.  Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells.

Authors:  A Goel; C R Boland; D P Chauhan
Journal:  Cancer Lett       Date:  2001-10-30       Impact factor: 8.679

5.  Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems.

Authors:  Stefan Gafner; Sang-Kook Lee; Muriel Cuendet; Sophie Barthélémy; Laurent Vergnes; Serge Labidalle; Rajendra G Mehta; Charles W Boone; John M Pezzuto
Journal:  Phytochemistry       Date:  2004-11       Impact factor: 4.072

6.  Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors.

Authors:  Michael A Pereira; Lianhui Tao; Wei Wang; Yingzhe Li; Asad Umar; Vernon E Steele; Ronald A Lubet
Journal:  Carcinogenesis       Date:  2004-06-17       Impact factor: 4.944

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells.

Authors:  Chi Chen; Guoxiang Shen; Vidya Hebbar; Rong Hu; Edward D Owuor; A-N Tony Kong
Journal:  Carcinogenesis       Date:  2003-06-19       Impact factor: 4.944

Review 9.  Curcumin as "Curecumin": from kitchen to clinic.

Authors:  Ajay Goel; Ajaikumar B Kunnumakkara; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

Review 10.  Tea and cancer.

Authors:  C S Yang; Z Y Wang
Journal:  J Natl Cancer Inst       Date:  1993-07-07       Impact factor: 13.506

View more
  4 in total

1.  The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Oncol       Date:  2011-12-07       Impact factor: 4.375

Review 2.  Lifestyle Modifications and Colorectal Cancer.

Authors:  Lukasz Durko; Ewa Malecka-Panas
Journal:  Curr Colorectal Cancer Rep       Date:  2014

3.  Quantitative metabolomics for investigating the value of polyamines in the early diagnosis and therapy of colorectal cancer.

Authors:  Ran Liu; Xiaohui Lin; Zuojing Li; Qing Li; Kaishun Bi
Journal:  Oncotarget       Date:  2017-12-04

4.  Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis.

Authors:  Shiran Shapira; Ari Leshno; Daniel Katz; Nitsan Maharshak; Gil Hevroni; Maayan Jean-David; Sarah Kraus; Lior Galazan; Ilan Aroch; Dina Kazanov; Aharon Hallack; Stewart Becker; Mark Umanski; Menachem Moshkowitz; Iris Dotan; Nadir Arber
Journal:  Therap Adv Gastroenterol       Date:  2017-11-28       Impact factor: 4.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.